ATE399022T1 - Zusammensetzung und verfahren zur verstärkung der immunantwort antigen-präsentierender zellen - Google Patents

Zusammensetzung und verfahren zur verstärkung der immunantwort antigen-präsentierender zellen

Info

Publication number
ATE399022T1
ATE399022T1 AT96936768T AT96936768T ATE399022T1 AT E399022 T1 ATE399022 T1 AT E399022T1 AT 96936768 T AT96936768 T AT 96936768T AT 96936768 T AT96936768 T AT 96936768T AT E399022 T1 ATE399022 T1 AT E399022T1
Authority
AT
Austria
Prior art keywords
immune response
enhancing
presenting cells
antigen
composition
Prior art date
Application number
AT96936768T
Other languages
English (en)
Inventor
Sam Sanderson
Michael Hollingsworth
Richard Tempero
Original Assignee
Univ Nebraska
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Nebraska filed Critical Univ Nebraska
Application granted granted Critical
Publication of ATE399022T1 publication Critical patent/ATE399022T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/472—Complement proteins, e.g. anaphylatoxin, C3a, C5a
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/57—IFN-gamma
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2869—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT96936768T 1995-10-20 1996-10-18 Zusammensetzung und verfahren zur verstärkung der immunantwort antigen-präsentierender zellen ATE399022T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US572795P 1995-10-20 1995-10-20

Publications (1)

Publication Number Publication Date
ATE399022T1 true ATE399022T1 (de) 2008-07-15

Family

ID=21717413

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96936768T ATE399022T1 (de) 1995-10-20 1996-10-18 Zusammensetzung und verfahren zur verstärkung der immunantwort antigen-präsentierender zellen

Country Status (9)

Country Link
US (5) US6821517B1 (de)
EP (1) EP0859625B1 (de)
JP (1) JP4125784B2 (de)
AT (1) ATE399022T1 (de)
AU (1) AU703120B2 (de)
CA (1) CA2232344C (de)
DE (1) DE69637571D1 (de)
ES (1) ES2309992T3 (de)
WO (1) WO1997014426A1 (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2309992T3 (es) 1995-10-20 2008-12-16 University Of Nebraska Board Of Regents Composiciones y procedimientos para incrementar las respuestas inmunes mediadas por celulas presentadoras de antigeno.
US20080286228A1 (en) * 1995-10-20 2008-11-20 Tarantolo Stefano R Compositions and methods for enhancing immune responses mediated by antigen-presenting cells
GB9930591D0 (en) * 1999-12-23 2000-02-16 Univ London Component for vaccine
US20030138434A1 (en) * 2001-08-13 2003-07-24 Campbell Robert L. Agents for enhancing the immune response
GB0208817D0 (en) * 2002-04-17 2002-05-29 European Molecular Biology Lab Embl Method for producing monoclonal antibodies
NZ540735A (en) * 2002-12-02 2008-08-29 Resistentia Pharmaceuticals Ab Methods and materials for treating inflammatory conditions using a polypeptide comprising a self-C5 amino acid segment and a non-self amino acid segment
WO2008039432A1 (en) * 2006-09-26 2008-04-03 Alexion Pharmaceuticals, Inc. Compositions and methods for enhancing an adjuvant
AU2008280436A1 (en) * 2007-07-24 2009-01-29 Stichting Katholieke Universiteit Radboud University Nijmegen Medical Centre Compositions and methods for generating an immune response in a subject
AU2008301888A1 (en) * 2007-09-20 2009-03-26 R. Bradley Jones Long interspersed nuclear element polypeptide compositions and methods of use thereof
US11260133B2 (en) * 2008-02-21 2022-03-01 Sanford-Burnham Medical Research Institute Methods and compositions related to peptides and proteins with C-terminal elements
BRPI1015424B1 (pt) 2009-06-22 2022-01-18 Burnham Institute For Medical Research Composição compreendendo um elemento cendr e uma co-composição e composição para uso no reforço da internalização, penetração, ou ambas, de uma co-composição
FR2955773B1 (fr) 2010-02-01 2017-05-26 Commissariat Energie Atomique Complexe moleculaire de ciblage des antigenes vers les cellules presentatrices d'antigene et ses applications pour la vaccination
WO2012006149A2 (en) * 2010-06-29 2012-01-12 Board Of Regents Of The University Of Nebraska Analogs of c5a and methods of using same
WO2013082535A2 (en) 2011-12-02 2013-06-06 Board Of Regents Of The University Of Nebraska Controlled-release peptide compositions and uses thereof
WO2013173827A2 (en) * 2012-05-18 2013-11-21 Board Of Regents Of The University Of Nebraska Methods and compositions for inhibiting diseases of the central nervous system
US20180066018A1 (en) 2015-03-11 2018-03-08 Board Of Regents Of The University Of Nebraska Conformationally stable analogs of the response selective c5a agonist ep67
CA3065552A1 (en) 2017-06-12 2018-12-20 Board Of Regents Of The University Of Nebraska Hydrochloride salts of c5a receptor agonist peptides
CA3154373A1 (en) 2018-09-14 2020-03-19 Prommune, Inc. Anti-parasitic immunological compositions
CN111544585B (zh) * 2019-02-11 2024-12-27 北京卡替医疗技术有限公司 一种可助推免疫细胞在体内扩增的佐剂
AU2021345483A1 (en) * 2020-09-18 2023-04-13 Othair Prothena Limited Multiepitope vaccine for the treatment of alzheimer's disease
US20250064894A1 (en) * 2022-01-06 2025-02-27 Washington University Methods and compositions for enhancement of tumor immunogenicity and stimulating anti-tumor immune responses in an animal
CN120168630B (zh) * 2025-05-23 2025-09-02 中国医学科学院医学生物学研究所 一种细胞器靶向的分子原位组装嵌合体及其应用

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2117514B (en) * 1982-03-29 1985-08-29 East Anglian Regional Health Polyvalent antiglobulin reagent
JPH0788398B2 (ja) * 1983-10-17 1995-09-27 サントリー株式会社 新規生理活性ポリペプチドおよびその製造法
GB2177514B (en) 1985-07-04 1988-07-06 Isc Chemicals Ltd Leak testing of electrical or electronic components
GB8610983D0 (en) * 1986-05-06 1986-06-11 Connaught Lab Enhancement of antigen immunogenicity
DE68924850T2 (de) 1988-06-14 1996-10-10 Cell Med Inc Heterofunktionelle zellular immunologische reagenzien, impfstoffe daraus und verwendungsverfahren.
US5032401A (en) * 1989-06-15 1991-07-16 Alpha Beta Technology Glucan drug delivery system and adjuvant
US5073627A (en) * 1989-08-22 1991-12-17 Immunex Corporation Fusion proteins comprising GM-CSF and IL-3
US5262303A (en) * 1989-10-13 1993-11-16 Trustees Of Boston University Ligand/anti-ligand assays for adherent proteins
US5840840A (en) * 1990-04-17 1998-11-24 The United States Of America As Represented By The Department Of Health And Human Services Selective RNase cytotoxic reagents
US6248332B1 (en) * 1990-10-05 2001-06-19 Medarex, Inc. Targeted immunostimulation with bispecific reagents
DE69130709T3 (de) * 1990-10-05 2005-12-22 Celldex Therapeutics, Inc. Gezielte immunostimulierung mit bispezifischen stoffen
JPH07108232B2 (ja) * 1990-10-09 1995-11-22 エム・ディ・リサーチ株式会社 ペプチド又は蛋白質の製造方法
GB9027767D0 (en) * 1990-12-21 1991-02-13 Cambridge Antibody Tech Binding substances
US5621083A (en) * 1991-11-04 1997-04-15 Xoma Corporation Immunotoxins comprising ribosome-inactivating proteins
AU671971B2 (en) * 1991-11-29 1996-09-19 Chiron Corporation Anti-cancer immunotherapeutic vector constructs
US5804187A (en) * 1992-11-16 1998-09-08 Cancer Research Fund Of Contra Costa Modified antibodies with human milk fat globule specificity
US5744144A (en) * 1993-07-30 1998-04-28 University Of Pittsburgh University Patent Committee Policy And Procedures Synthetic multiple tandem repeat mucin and mucin-like peptides, and uses thereof
AUPM322393A0 (en) * 1993-12-24 1994-01-27 Austin Research Institute, The Mucin carbohydrate compounds and their use in immunotherapy
US5614370A (en) * 1994-03-18 1997-03-25 Merck & Co., Inc. Assay to identify human C5a antagonists and agonists
US5696230A (en) 1994-08-31 1997-12-09 The Board Of Regents Of The University Of Nebraska High-affinity response-selective C-terminal analogs of C5a anaphylatoxin
US6086875A (en) * 1995-01-17 2000-07-11 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of immunogens
GB9501079D0 (en) * 1995-01-19 1995-03-08 Bioinvent Int Ab Activation of T-cells
ES2309992T3 (es) * 1995-10-20 2008-12-16 University Of Nebraska Board Of Regents Composiciones y procedimientos para incrementar las respuestas inmunes mediadas por celulas presentadoras de antigeno.
US6080409A (en) * 1995-12-28 2000-06-27 Dendreon Corporation Immunostimulatory method
FR2775977B1 (fr) * 1998-03-10 2000-06-23 Oreal Composes lipidiques derives des bases sphingoides, leur procede de preparation et leurs utilisations en cosmetique et en dermopharmacie
WO2003082329A2 (en) * 2002-03-01 2003-10-09 The Board Of Regents Of The University Of Nebraska Compositions and compounds for use as molecular adjuvant for a nicotine vaccine

Also Published As

Publication number Publication date
DE69637571D1 (de) 2008-08-07
AU7460896A (en) 1997-05-07
US7358087B2 (en) 2008-04-15
EP0859625A4 (de) 2004-03-03
EP0859625B1 (de) 2008-06-25
AU703120B2 (en) 1999-03-18
US20050025784A1 (en) 2005-02-03
US20070031445A1 (en) 2007-02-08
JPH11515005A (ja) 1999-12-21
US7063847B1 (en) 2006-06-20
EP0859625A1 (de) 1998-08-26
US20020091234A1 (en) 2002-07-11
US7291336B2 (en) 2007-11-06
US6821517B1 (en) 2004-11-23
WO1997014426A1 (en) 1997-04-24
ES2309992T3 (es) 2008-12-16
CA2232344C (en) 2005-04-05
JP4125784B2 (ja) 2008-07-30
CA2232344A1 (en) 1997-04-24

Similar Documents

Publication Publication Date Title
ATE399022T1 (de) Zusammensetzung und verfahren zur verstärkung der immunantwort antigen-präsentierender zellen
DE69534946D1 (de) Verwendung von nackten Polynukleotiden zur Herstellung eines Medikaments für die Behandlung von Tumoren
TR200200117T2 (tr) Nükleotid analog kompozisyonlar
DE69636891D1 (de) Immunstimulierende zusammensetzung und verfahren
AU2210899A (en) Use of a phosphatidylserine/polypeptide conjugate for inducing autoimmunity in the treatment of cancers
WO2000062800A3 (en) Adjuvant composition comprising saponin and an immunostimulatory oligonucleotide
IL125590A (en) Peptide immunogens, process for their preparation and use thereof as vaccines against allergies
TR199900848T2 (xx) Oksadiazoller, elde edilmeleri ve ila� olarak kullan�mlar�.
BR9811037A (pt) Utilização de ligantes mhc classe ii como coadjuvante para vacinação e de lag-3 no tratamento do câncer
ATE223702T1 (de) Verfahren und zusammensetzungen zur mikrokapselung von adjuvantien
DE69839273D1 (de) Krebs immuntherapie mit semi-allogenen zellen
DE69620271D1 (de) Polyribosylribitol-phosphat enthaltende Haemophilus-influenzae-Typ-b-Impfstoffzubereitung und Verfahren zur deren Herstellung
IS6558A (is) Blandaðar sjúkdómsmeðferðir með æðaskaðandi virkni
CA2362578A1 (en) Tumor vaccines
WO2005067460A3 (en) Epha2 vaccines
WO1997005899A3 (en) Novel vaccines and pharmaceutical compositions using membrane vesicles of microorganisms, and methods for preparing same
EP0422164B1 (de) Multivalentes immunogen lmi
BR0207528A (pt) Anticorpo, composição farmacêutica, e, usos de uma quantidade efetiva de um agente, de uma quantidade terapeuticamente efetiva de um anticorpo para il-22, de uma quantidade imunogênica do antìgeno e uma quantidade aumentadora de imunogenicidade de il-22 em combinação, de uma quantidade efetiva do anticorpo ou fragmento do mesmo e de uma quantidade suficiente de anticorpo ou fragmento ligado a antìgeno do mesmo
DE59708495D1 (de) Feste instant-release-darreichungsformen und verfahren zu ihrer herstellung
EP1820514A3 (de) Therapeutische Zusammensetzungen, die durch Wechseln des Antigens eine Immunantwort produzieren
Fenton et al. A phase I randomized study of subcutaneous adjuvant IL-2 in combination with an autologous tumor vaccine in patients with advanced renal cell carcinoma
MY127452A (en) Vaccines.
DE69928523D1 (de) Verotoxin b untereinheit zur immunisierunug
Bonavida et al. Multistage model of natural killer cell-mediated cytotoxicity involving NKCF as soluble cytotoxic mediators
CA2460042A1 (en) Inhibition of antigen presentation with poorly catabolized polymers

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0859625

Country of ref document: EP